Australia's Nyrada rises on positive pre-clinical results for cardiovascular drug

Nyrada

01/10/2024 07:00

** Shares of Nyrada  NYR.AX  rise as much as 123.1% to
A$0.145, their biggest intraday pct jump since Feb 28
    ** Stocks of the pharma co, which specialises in
neurological and cardiovascular treatments, hits its highest
level since April 8
    ** Co says pre-clinical study showed its NYR-BI03 drug has
strong efficacy limiting cardiovascular damage from coronary
heart disease 
    ** Adds that drug provides significant cardio protection
after tissue damage caused when blood flow is restored after an
interruption in oxygen supply
    ** More than 11.5 mln shares change hands, 36.4 times the
30-day average of ~316,112 shares 
    ** Stock up 400% YTD, including current session's moves

    

 (Reporting by Nikita Maria Jino in Bengaluru)
 ((Nikita.Jino@thomsonreuters.com;))